Publication:
The effectiveness of enterprise stent use on the treatment of intracranial atherosclerosis disease

dc.contributor.authorArı, Oğuz
dc.contributor.authorNas, Ömer F.
dc.contributor.authorİnecikli, Mehmet F.
dc.contributor.authorHakyemez, Bahattin
dc.contributor.buuauthorNAS, ÖMER FATİH
dc.contributor.buuauthorİNECİKLİ, MEHMET FATİH
dc.contributor.buuauthorHAKYEMEZ, BAHATTİN
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.
dc.contributor.researcheridAAK-5124-2020
dc.contributor.researcheridAAI-2318-2021
dc.contributor.researcheridAAG-8561-2021
dc.date.accessioned2024-09-23T06:21:57Z
dc.date.available2024-09-23T06:21:57Z
dc.date.issued2022-04-07
dc.description.abstractObjective: To examine the clinical outcome of Enterprise stent in patients with severe and symptomatic intracranial atherosclerosis.Material and method: Twenty-five patients who underwent Enterprise stenting between January 2012 and March 2019 were included in this study. Exclusion criteria were previous intracranial stenting and inadequate follow-up. Technical success rates of the procedures were recorded. Clinical outcome was evaluated with pre- and post-treatment modified Rankin Scale scores. The patients were monitored for 18 months clinically and for 14.3 months radiologically.Results: The mean age of the 15 males and 10 females was 61.6 +/- 8.19. Of these 25 patients, 6 (24%) were in the anterior system and 19 (76%) were in posterior system. The mean degree of pre-treatment stenosis was 86.4% +/- 7 with the mean lesion length of 12.5 +/- 7.5 mm. The residual stenosis rate was 23.8% +/- 8.81. Technical success rate was 100%. There were two major complications within the first 30 days (8%). Late major complications (after 30 days) occurred in one case (4%). Stent restenosis was detected in two patients (8%). No intracranial bleeding or mortality was observed.Conclusion: In this single-center study, we achieved high technical success and tolerable complication rates. Enterprise stent may be a good treatment alternative for severe intracranial stenosis especially in patients resistant to medical treatment when correct patient selection is made. However, further randomized controlled studies, including more cases should be carried out.
dc.identifier.doi10.1177/19714009221083143
dc.identifier.endpage618
dc.identifier.issn1971-4009
dc.identifier.issue5
dc.identifier.startpage612
dc.identifier.urihttps://doi.org/10.1177/19714009221083143
dc.identifier.urihttps://journals.sagepub.com/doi/10.1177/19714009221083143
dc.identifier.urihttps://hdl.handle.net/11452/45017
dc.identifier.volume35
dc.identifier.wos000780143600001
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.journalNeuroradiology Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAggressive medical therapy
dc.subjectUndersized angioplasty
dc.subjectInitial-experience
dc.subjectArterial-stenosis
dc.subjectWingspan
dc.subjectStroke
dc.subjectIntracranial atherosclerosis
dc.subjectEnterprise stent
dc.subjectEndovascular treatment
dc.subjectNeurosciences & neurology
dc.titleThe effectiveness of enterprise stent use on the treatment of intracranial atherosclerosis disease
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication2aa7fdf5-f110-441f-b7ea-0d829a69f47b
relation.isAuthorOfPublicationd03fbfc2-9e28-4ae3-b1a8-bf0fbedccbd1
relation.isAuthorOfPublication9ad8c0f1-5154-4a82-b029-77c58cb35066
relation.isAuthorOfPublication.latestForDiscovery2aa7fdf5-f110-441f-b7ea-0d829a69f47b

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ari_vd_2022.pdf
Size:
756.77 KB
Format:
Adobe Portable Document Format

Collections